Sergey Badalyan, Medical Oncology Resident at Yeolyan Hematology and Oncology Center, Assistant Managing Editor at OncoDaily Medical Journal, shared a post on LinkedIn:
“Another oral abstract that drew considerable attention during the amyloidosis and multiple myeloma precursors session at EHA 2026 was presented by Dr. Ashutosh Wechalekar.
The phase III CARES study evaluated anselamimab, a first-in-class anti-fibril monoclonal antibody designed to directly target and promote the clearance of amyloid deposits in patients with newly diagnosed cardiac AL amyloidosis.
While the study did not meet its primary composite endpoint in the overall population, a prespecified analysis showed a notable reduction in all-cause mortality and cardiovascular hospitalizations among patients with κ (kappa) light-chain disease. These findings raise important questions about potential biological differences between κ and λ amyloidosis and may help shape future therapeutic strategies in this challenging disease.
What I found particularly interesting was the shift in focus beyond plasma cell-directed therapy alone. For decades, treatment has largely centered on suppressing the underlying clone; approaches aimed at directly removing existing amyloid deposits could represent an important addition to the therapeutic arsenal.”
More posts featuring Sergey Badalyan.